![memed](https://nocamels.com/wp-content/uploads/2021/09/memed3-350x234.jpg)
MeMed Raises $93M To Decode Body’s Immune Response
MeMed has developed an immune-based protein signature, which distinguishes between bacterial and viral infections.
January 11, 2022
![Illustration of cells.](https://nocamels.com/wp-content/uploads/2020/02/Depositphotos_11260302_l-2015-350x263.jpg)
Israel’s NeoTx Raises $45M For Cancer Immunotherapy Treatment
The Rehovot-based company uses its Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.
February 20, 2020